Brought to you by 
CNS drug developer Newron grosses CHF118mm in IPO on SWX
18 Dec 2006
Executive Summary
Italian firm Newron Pharmaceuticals SPA (CNS diseases) has raised CHF118mm ($99mm) through its initial public offering on the SWX Swiss Exchange. It sold 2.15mm shares for CHF55 each, landing in the upper end of its planned CHF45-60 price range.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CNS drug developer Newron grosses CHF118mm in IPO on SWX
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice